Cetuximab vs CPO301
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Head and Neck Squamous Cell Carcinoma
Shared mechanism: EGFR · full Head and Neck Squamous Cell Carcinoma pipeline
Cetuximab
Marketed by Eli Lilly and partners
NCT00122460 · Phase 3 · completed
The trial randomized 442 participants to cetuximab plus chemotherapy or chemotherapy alone, but treatment was open-label rather than blinded. Its objective primary endpoint, overall survival, was statistically significant in favor of cetuximab, although the lack of blinding limits the design strength.
Next expected readout: December 2026 · NCT06943820 (registry estimate)
Reported efficacy
Overall Survival Time (OS) (time from randomization to death or last day known to be alive, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007): Overall Survival Time (OS) (time from randomization to death or last day known to be alive, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007): Cetuximab Plus Chemotherapy 10.1 months (95% CI 8.6 to 11.2) | Chemotherapy Alone 7.4 months (95% CI 6.4 to 8.3) (met)
Result source: NCT00122460
CPO301
Developed by Conjupro Biotherapeutics, Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2028 · NCT07254585 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Head and Neck Squamous Cell Carcinoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
CPO301: no structured comparison results are available for Head and Neck Squamous Cell Carcinoma.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cetuximab's landscape · CPO301's landscape